| Study characteristics |
| Methods |
Allocation concealment: computer‐generated randomization with two per block design, 1:1 ratio
Blinding of study: No |
| Participants |
871 patients randomised
Excluded: 34
Mainly leukaemia, but also other cancer patients and patients receiving bone marrow transplantation |
| Interventions |
Voriconazole: Intravenous loading dose of 6 mg/kg twice within the first 24 hours, maintenance dose of 3 mg/kg twice daily, or 200 mg orally twice daily after at least 3 days of intravenous therapy
Liposomal amphotericin B: 3 mg/kg/day intravenously |
| Outcomes |
Total mortality
Invasive fungal infections
Use of escape drugs
Nephrotoxicity
Other adverse events |
| Notes |
Follow‐up period (days): Median of 7 days in both groups. Non‐inferiority trial with composite endpoint
Support: Pfizer |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
High risk |
C ‐ Inadequate |
| Blinding (performance bias and detection bias)
All outcomes |
High risk |
|
